Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy

about

Progress in the clinical detection of heterogeneity in breast cancer Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.

P2860

Q28079224-E350E858-7128-4EB5-B52C-FF565DF76631 Q41436889-F8FD56C3-ACB5-4639-BFB7-96AB2C838922

P2860

Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy

Item

http://www.wikidata.org/entity/Q36949355

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Ability of contrast-enhanced u ...... er to neoadjuvant chemotherapy

@en

type

Item

label

Ability of contrast-enhanced u ...... er to neoadjuvant chemotherapy

@en

prefLabel

Ability of contrast-enhanced u ...... er to neoadjuvant chemotherapy

@en

P1476

Ability of contrast-enhanced u ...... er to neoadjuvant chemotherapy

@en

P2093

Ai Amioka

http://www.w3.org/2001/XMLSchema#string

Akiko Emi

http://www.w3.org/2001/XMLSchema#string

Hideo Shigematsu

http://www.w3.org/2001/XMLSchema#string

Keiko Kajitani

http://www.w3.org/2001/XMLSchema#string

Morihito Okada

http://www.w3.org/2001/XMLSchema#string

Noriko Gouda

http://www.w3.org/2001/XMLSchema#string

Norio Masumoto

http://www.w3.org/2001/XMLSchema#string

Takayuki Kadoya

http://www.w3.org/2001/XMLSchema#string

P2860

Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Transplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumors

Magnetic resonance mammography has limited ability to estimate pathological complete remission after primary chemotherapy or radiofrequency ablation therapy.

Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATA

Clinical applications of PET in oncology.

Evolving role of positron emission tomography in breast cancer imaging.

Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?

P304

303-309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYV215

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26848078

http://www.w3.org/2001/XMLSchema#string

P932

4886139

http://www.w3.org/2001/XMLSchema#string

Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy

about

P2860

P2860

Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932